Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M.
Eur Respir J · review-article; review; journal article · DOI 10.1183/09031936.00174914 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för nintedanib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
10 hitsTolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K.
J Thorac Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1097/jto.0000000000000395Nintedanib: from discovery to the clinic.
Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.
J Med Chem · review; journal article · DOI 10.1021/jm501562aLight-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.
Huu VA, Luo J, Zhu J, Zhu J, Patel S, Boone A, Mahmoud E, McFearin C, Olejniczak J, de Gracia Lux C, Lux J, Fomina N, Huynh M, Zhang K, Almutairi A.
J Control Release · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jconrel.2015.01.001Nintedanib: first global approval.
McCormack PL.
Drugs · journal article · DOI 10.1007/s40265-014-0335-0Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Barrueco J, Gaschler-Markefski B, Griebsch I, Palmer M, Reck M, LUME-Lung 1 Study Group.
Eur J Cancer · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ejca.2014.11.015Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.
Cancer Lett · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.canlet.2014.12.027Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Popat S, Mellemgaard A, Fahrbach K, Martin A, Rizzo M, Kaiser R, Griebsch I, Reck M.
Future Oncol · research support, non-u.s. gov't; network meta-analysis; journal article · DOI 10.2217/fon.14.290Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY.
J Neurooncol · clinical trial, phase ii; journal article · DOI 10.1007/s11060-014-1631-yNintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT, Shiau CW, Li YS, Chang CW, Huang JW, Hsueh TT, Yu HC, Chen KF.
J Hepatol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jhep.2014.03.017